A theme focused on expanding orders and sales in growth areas by broadening the scope from hepatitis drug efficacy evaluation to safety evaluation, including DMPK and Tox (drug metabolism and pharmacokinetics, and toxicity). It covers expansion of the target areas for nonclinical evaluation services and revenue growth.